Market Update (NYSE:PFE): Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

[Business Wire] – Pfizer Inc. announced today that the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Manageme Read more on this. Pfizer Inc. (PFE) , valued at $213.79B, started the session at $34.77. Looking at the stock, its one day range is $34.67 to $35.33 with its 52-week range being $28.25 to $36.46. PFE shares are currently priced at 14.28x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.21x earnings multiple. And for income investors, the company pays shareholders $1.20 per share annually in dividends, yielding 3.44%. Consensus earnings for the current quarter by the 15 sell-side analysts covering the stock is an estimate of $0.62 per share, which would be $0.06 better than the year-ago quarter and a $0.03 sequential increase. What we find to be interesting is that the full-year EPS estimate of $2.44 is a $0.24 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $12.94 Billion. If realized, that would be a 9.20% increase over the year-ago quarter. More recently, Berenberg Initiated PFE at Hold (May 12, 2016). Previously, Sun Trust Rbsn Humphrey upgraded PFE from Reduce to Neutral. The average price target for PFE shares is $38.67, which is 11.22% above where the stock opened this morning. See more in (NYSE:PFE) Similar Articles: Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer Market Update (NYSE:PFE): Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications